ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Health-related Quality of Life in European Older Adults with Respiratory Syncytial Virus Over Three Respiratory Syncytial Virus Seasons.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Burden of Respiratory Syncytial Virus Among Older Adults With an Acute Respiratory Infection: A Prospective Study in Six European Countries.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is an important cause of respiratory illness, affecting individuals of all ages. RSV can cause severe disease in older adults, but the disease burden and how it affects the health-related quality of life (HRQoL) is not well characterized.
methodsThis multicenter, cross-sectional study conducted over three RSV seasons (October 2021-April 2024) in six European countries enrolled adults ≥60 years of age (YOA) who presented to general practitioners or outpatient clinics with an acute respiratory infection (ARI) and who were not vaccinated against RSV. The symptom duration, the effect of medically-attended confirmed RSV-ARI (cRSV-ARI) on symptomology (InFLUenza Patient-Reported Outcome [FLU-PRO] questionnaire) and HRQoL (EuroQoL-5 Dimension [EQ-5D-3L] questionnaire) as well as the healthcare resource utilization and working days lost were assessed.
resultsWe analyzed 136 participants with a medically-attended cRSV-ARI. The median duration of any ARI symptom was 2.0-19.0 days. cRSV-ARI symptoms mostly affected the chest/respiratory domain (mean score: 1.72; standard deviation [SD]: 0.76) and the nose domain (mean score: 1.58; SD: 1.00). The mean country-specific cRSV-ARI utility scores ranged from 0.81 on Day 1 to 0.90 on Day 29. On Day 57, the score was 0.84. A trend for an increased effect on HRQoL was observed in participants with lower respiratory tract disease. The mean duration of treatment was 16.3 (SD: 11.9) days, and 27.8% of participants in active employment stayed home from work.
conclusionsmedically-attended cRSV-ARIs substantially affect the symptomology and HRQoL of European adults ≥60 YOA who were not vaccinated against RSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.